[Standardization of evaluation for target molecule in cancer therapy].
The individualized-therapy for the gastrointestinal tract cancer is started by the emergence of molecular targeted-therapy. The patients' selection for treatment is now performed by evaluating the expression level of the targeted molecules and/or the gene mutation analysis using the pathological specimens. Pathologists should make diagnosis and select patients for the fittest molecular targeted therapy in colon cancer, stomach cancer and gastrointestinal stromal tumor(GIST). In the present paper, we focused and discussed the points of the evaluation of the targeted-molecule in pathological materials for selecting patients using the examples of HER2 test in gastric cancer and K-RAS muation in colon cancer.